Copyright
©The Author(s) 2025.
World J Cardiol. Mar 26, 2025; 17(3): 103668
Published online Mar 26, 2025. doi: 10.4330/wjc.v17.i3.103668
Published online Mar 26, 2025. doi: 10.4330/wjc.v17.i3.103668
Table 1 Indications for fetal echocardiography
| Indications for fetal echocardiography | Indicated | May be considered | Not indicated |
| Maternal factors (absolute risk) | |||
| Pre-gestational diabetes | Yes | - | - |
| Gestational diabetes diagnosed in first or early second trimester | - | Yes | - |
| Gestational diabetes diagnosed after second trimester | - | - | Yes |
| Phenylketonuria (phenylalanine level > 10 mg/dL) | Yes | - | - |
| Autoimmune disease: SSA/SSB positive | Yes | - | - |
| In vitro fertilization | - | Yes | - |
| Confirmed fetal infection (TORCH- and parvovirus-B19-positive) | Yes | - | - |
| First- or second-degree relative with disease of Mendelian inheritance and history of childhood cardiac manifestations | Yes | - | - |
| Family history of CHD: First-degree relative | Yes | - | - |
| Family history of CHD: Second-degree or more distant relative | - | - | Yes |
| Obesity (BMI > 30 kg/m2) | - | - | Yes |
| Retinoids | Yes | - | - |
| ACE inhibitors | - | Yes | - |
| Paroxetine | - | Yes | - |
| Other selective serotonin reuptake inhibitors | - | - | Yes |
| Anticonvulsants | - | - | Yes |
| Alcohol | - | - | Yes |
| Lithium | - | - | Yes |
| Warfarin | - | - | Yes |
| Fetal factors identified during screening (absolute risk) | |||
| Suspected cardiac structural anomaly | Yes | - | - |
| Fetal hydrops | Yes | - | - |
| Extracardiac anomaly known to be associated with CHD | Yes | - | - |
| Persistent fetal tachycardia (heart rate ≥ 180 bpm) | Yes | - | - |
| Suspected heart block or persistent fetal bradycardia (heart rate ≤ 110 bpm) | Yes | - | - |
| Frequent episodes or persistently irregular cardiac rhythm | Yes | - | - |
| Suspected abnormality of cardiac function or cardiomegaly | Yes | - | - |
| Chromosomal abnormalities | Yes | - | - |
| Monochorionic twinning | Yes | - | - |
| Nuchal translucency 3.0-3.4 mm | Yes | - | |
| Nuchal translucency ≥ 3.5 mm | Yes | - | - |
| Single umbilical artery in isolation | - | - | Yes |
| Other considerations | |||
| Non-cardiac “soft marker” for aneuploidy | - | - | Yes |
| Abnormal serum analytes (e.g. α-fetoprotein level) | - | - | Yes |
| Echogenic intracardiac focus | - | - | Yes |
| Prenatal fever or viral infection with seroconversion only | - | - | Yes |
- Citation: Bokhari SFH, Faizan Sattar SM, Mehboob U, Umais M, Ahmad M, Malik A, Bakht D, Iqbal A, Dost W. Advancements in prenatal diagnosis and management of hypoplastic left heart syndrome: A multidisciplinary approach and future directions. World J Cardiol 2025; 17(3): 103668
- URL: https://www.wjgnet.com/1949-8462/full/v17/i3/103668.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i3.103668
